Aims: 15-18% of Breast cancer is a “Triple Negative Breast Cancer”, without estrogen, progesterone and HER2 receptors. This type of tumour has an aggressive behaviour and does not respond to conventional hormonal or anti-HER2 therapies. In this article we examine different cases of Triple Negative Breast Cancer (TNBC) in the ederly in order to show a diagnostic-therapeutic algorithm. Materials and methods: In this paper there were examined three heterogeneous clinical case of Triple Negative Breast Cancer (TNBC). Results: TNBC has an aggressive behaviour and the only treatment that guarantees a response is chemotherapy. The first of the three patients was free relapse for 15 months; the second had a relapse in homolateral breast after 12 months with a liver meta- stases; the third patient, seven years after a TNBC, had a second breast tumour, but this time hormonal positive. Conclusion: TNBC is still a challenge for surgeons and oncologists but soon new knowledge helps in the diagnosis, in the surgical and in the pharmacological treatment of this disease
Triple negative breast cancer in elderly patients clinical approach
CATANIA, Vito Emanuele;CAMMISULI, Fernando
2014-01-01
Abstract
Aims: 15-18% of Breast cancer is a “Triple Negative Breast Cancer”, without estrogen, progesterone and HER2 receptors. This type of tumour has an aggressive behaviour and does not respond to conventional hormonal or anti-HER2 therapies. In this article we examine different cases of Triple Negative Breast Cancer (TNBC) in the ederly in order to show a diagnostic-therapeutic algorithm. Materials and methods: In this paper there were examined three heterogeneous clinical case of Triple Negative Breast Cancer (TNBC). Results: TNBC has an aggressive behaviour and the only treatment that guarantees a response is chemotherapy. The first of the three patients was free relapse for 15 months; the second had a relapse in homolateral breast after 12 months with a liver meta- stases; the third patient, seven years after a TNBC, had a second breast tumour, but this time hormonal positive. Conclusion: TNBC is still a challenge for surgeons and oncologists but soon new knowledge helps in the diagnosis, in the surgical and in the pharmacological treatment of this diseaseFile | Dimensione | Formato | |
---|---|---|---|
2014 TNBC PUBBLICATO.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
125.96 kB
Formato
Adobe PDF
|
125.96 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.